- Home
- XRTX
as 07-26-2024 4:00pm EST
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
| Founded: | 2011 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.7M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 172.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $67.72 | Next Earning Date: | 08-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest XORTX Therapeutics Inc. News
XRTX Breaking Stock News: Dive into XRTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
XORTX to Present at BIO International Convention 2024
GlobeNewswire
2 months ago
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
GlobeNewswire
3 months ago
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
GlobeNewswire
3 months ago
XORTX Announces Publication of Key Research in ADPKD
GlobeNewswire
4 months ago
XORTX Welcomes New Member to the Board of Directors
GlobeNewswire
4 months ago
XORTX Announces Participation in Spring 2024 Investor Conferences
GlobeNewswire
4 months ago
XORTX Announces New Clinical Advisory Board Member
News Direct
4 months ago
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
Compare XRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XRTX XORTX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.